Get the Stockscreener App
2.92
2.99%
-0.09
After Hours:
2.87
-0.05
-1.71%
Absci Corp stock is traded at $2.92, with a volume of 7.13M.
It is down -2.99% in the last 24 hours and up +6.57% over the past month.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
See More
Previous Close:
$3.01
Open:
$2.9
24h Volume:
7.13M
Relative Volume:
2.01
Market Cap:
$439.08M
Revenue:
$2.82M
Net Income/Loss:
$-114.60M
P/E Ratio:
-3.2294
EPS:
-0.9042
Net Cash Flow:
$-81.94M
1W Performance:
+2.10%
1M Performance:
+6.57%
6M Performance:
+10.19%
1Y Performance:
-4.89%
1-Day Range:
$2.80
$3.11
1-Week Range:
$2.79
$3.20
52-Week Range:
$2.01
$5.228
Absci Corp Stock (ABSI) Company Profile
Name
Absci Corp
Sector
Industry
Phone
(360) 949-1041
Address
18105 SE MILL PLAIN BLVD, VANCOUVER
Compare ABSI vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
2.92 | 452.62M | 2.82M | -114.60M | -81.94M | -0.9042 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-02-25 | Initiated | JP Morgan | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jan-22-25 | Initiated | Needham | Buy |
| Oct-02-24 | Initiated | Guggenheim | Buy |
| Jul-03-24 | Initiated | Morgan Stanley | Overweight |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-04-23 | Initiated | H.C. Wainwright | Buy |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Jul-18-22 | Initiated | Truist | Buy |
| Mar-02-22 | Resumed | Cowen | Market Perform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Nov-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Aug-16-21 | Initiated | BofA Securities | Neutral |
| Aug-16-21 | Initiated | Cowen | Market Perform |
| Aug-16-21 | Initiated | Credit Suisse | Outperform |
| Aug-16-21 | Initiated | Stifel | Hold |
View All
Absci Corp Stock (ABSI) Latest News
Absci, DigitalOcean and other big stocks moving lower in Wednesday's pre-market session - MSN
Absci price target lowered to $4.20 from $4.32 at Morgan Stanley - TipRanks
A Quick Look at Today's Ratings for Absci Corp(ABSI.US), With a Forecast Between $4.2 to $8 - 富途牛牛
Absci (NASDAQ:ABSI) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Absci, DigitalOcean And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Why Blaize Holdings Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket - Benzinga
Absci Reports Positive ABS-201 Clinical Progress, Strong Financials, and Advances AI-Designed Therapeutics Pipeline in 2025 Results - Minichart
Absci Corp (ABSI) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience By GuruFocus - Investing.com Canada
TD Cowen Maintains Absci Corp(ABSI.US) With Buy Rating - Moomoo
Absci reports Q4 EPS (20c), consensus (17c) - TipRanks
Absci’s AI-Native Integrated Drug Creation Platform: Advancing Antibody Therapeutics and Biopharma Innovation - Minichart
Absci Corporation (ABSI) reports Q4 loss, misses revenue estimates - MSN
Absci Corp’s 2025 Q4 Call: FDA Delays, Oncology Partnership Shifts, and ABS-201 Timeline Contradictions - Bitget
Absci Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Absci’s Q4 2025 earnings miss forecasts, stock dips - Investing.com
Absci Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Absci Corporation (ABSI) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Absci Corp. (NASDAQ:ABSI) Reports Mixed Q4 Results Amid Clinical Progress - ChartMill
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Absci (NASDAQ: ABSI) deepens 2025 loss while pushing ABS-201 toward key data - Stock Titan
Absci earnings missed by $0.02, revenue fell short of estimates - Investing.com
Absci (NASDAQ:ABSI) Issues Quarterly Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
Absci shares slip nearly 4% on Q4 revenue miss, wider loss than expected - Investing.com
Absci 10-K: Partner revenue $2.8M, Net loss $115.2M, EPS $(0.84) - TradingView
ABSCI ($ABSI) Releases Q4 2025 Earnings - Quiver Quantitative
Absci (NASDAQ: ABSI) highlights ABS-201 trial progress and AI drug platform - Stock Titan
Absci's hair-loss drug is well tolerated in first 3 cohorts - Stock Titan
AbSci Corp options imply 13.4% move in share price post-earnings - TipRanks
Absci forms advisory board for endometriosis drug program - Investing.com
Absci taps Yale, Mayo experts for non-hormonal endometriosis drug - Stock Titan
Earnings Scheduled For March 24, 2026 - Benzinga
Absci Q4 2025 Earnings Call Transcript - MarketBeat
Earnings To Watch: Absci Corp (ABSI) Reports Q4 2025 Result - GuruFocus
ABSI Technical Analysis | Trend, Signals & Chart Patterns | ABSCI CORP (NASDAQ:ABSI) - ChartMill
Form 8K Absci Corp For: 14 January - Investing.com
Absci Corp expected to post a loss of 19 cents a shareEarnings Preview - TradingView
ABSI PE Ratio & Valuation, Is ABSI Overvalued - Intellectia AI
ABSI Forecast, Price Target & Analyst Ratings | ABSCI CORP (NASDAQ:ABSI) - ChartMill
Earnings Preview: Absci Corp to Report Financial Results Post-market on March 24 - 富途牛牛
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
Needham Reiterates Buy Rating for Absci (ABSI) with Unchanged Pr - GuruFocus
Absci (NASDAQ:ABSI) Given Buy Rating at Needham & Company LLC - MarketBeat
Heights Capital Management Inc. Makes New Investment in Absci Corporation $ABSI - MarketBeat
Absci Corporation (NASDAQ:ABSI) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Absci (ABSI) CLO receives major RSU and stock option grants - Stock Titan
Absci (NASDAQ: ABSI) CFO receives new RSU and stock option awards - Stock Titan
Absci (NASDAQ: ABSI) SVP Bedrick gets RSUs, options and tax withholding - Stock Titan
Absci (NASDAQ: ABSI) CEO granted 2M+ equity units and has shares withheld for taxes - Stock Titan
Absci Corp chief innovation officer Busch buys $229,000 in stock By Investing.com - Investing.com Australia
Absci (NASDAQ:ABSI) Insider Acquires $229,000.00 in Stock - MarketBeat
Absci Corp chief innovation officer Busch buys $229,000 in stock - Investing.com India
Absci Corp Stock (ABSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):